欧盟准备批准罗歇(Roche)的无化疗法Lunsumio, The EU is poised to approve Roche’s chemotherapy-free Lunsumio for relapsed follicular lymphoma.

欧洲医药署的CHMP建议批准Roche的下皮Lunsumio治疗, 这是针对复发或复发性脊髓炎淋巴瘤成人的双分抗体治疗。 The European Medicines Agency's CHMP has recommended approval for Roche's subcutaneous Lunsumio, a bispecific antibody treatment for adults with relapsed or refractory follicular lymphoma. 这种免疫疗法提供了一种无化疗选择,预计不久将获得欧洲联盟委员会的最后销售授权。 This immunotherapy offers a chemotherapy-free option and is expected to receive final marketing authorization from the European Commission soon.